B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response.

ABSTRACT:

Purpose

Targeted treatments are desperately needed for ependymomas. Chimeric antigen receptor (CAR) T cells have immense potential to transform patient outcomes. However, CAR T-cell therapy for ependymomas has been largely understudied. In this study, we explore the potential of targeting B7 homolog 3 (B7-H3/CD276) with CAR T cells to treat pediatric ependymomas.

Experimental design

We profiled B7-H3 protein expression in 44 pediatric ependymoma samples by IHC. We generated second-generation human B7-H3.CAR T cells and examined their anti-ependymoma activity in six in vitro and two in vivo xenograft models. We validated findings using HER2-targeted CAR T cells. In addition, we used murine B7-H3.CAR T cells to evaluate in vivo antitumor activity in a fully syngeneic supratent

SUBMITTER: Mehta S 

PROVIDER: S-EPMC12402791 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature